Welcome to our dedicated page for ALUMIS SEC filings (Ticker: ALMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alumis Inc. filings document material events for a Nasdaq-listed biopharmaceutical issuer, including 8-K reports on clinical data, corporate presentations, operating and financial results and capital-structure activity. The disclosures identify common stock listed under ALMS on The Nasdaq Global Select Market and note the company’s emerging growth company status.
The filing record covers envudeucitinib presentations and press releases, financial-results exhibits, common-stock offering disclosures, and shareholder voting matters from the annual meeting and proxy process. These documents frame the company’s governance, material agreements, capital structure and clinical or regulatory disclosure around its TYK2 inhibitor pipeline.
Alumis Inc. director Srinivas Akkaraju reported new equity awards and updated fund holdings. He received a grant of 3,553 shares of common stock in the form of restricted stock units, plus stock options covering 15,528 shares at an exercise price of $28.14 per share. Both the RSUs and options vest on the first anniversary of the grant date, and in any event are fully vested by the issuer's 2027 annual stockholder meeting, subject to his continuous service and with full vesting upon a qualifying change in control.
After these grants, he directly holds 3,553 shares and options on 15,528 shares, and is associated with indirect holdings of 1,853,488 shares through Samsara Opportunity Fund, L.P. and 4,491,731 shares through Samsara BioCapital, L.P. The fund positions are held by those partnerships, with Akkaraju’s beneficial interest limited to his pecuniary stake.
Alumis Inc. shareholder update: AyurMaya Capital Management Company, L.P. and David E. Goel report beneficial ownership of 15,139,707 shares of Alumis common stock, representing 12.3% of the class. This percentage is based on 123,432,027 voting common shares outstanding as of May 5, 2026.
The amendment states that the change in ownership percentage results solely from a change in Alumis’s shares outstanding, not from new share purchases or sales. The reporting persons have shared voting and dispositive power over all reported shares and confirm no transactions in Alumis stock during the past 60 days.
Alumis Inc. held its 2026 Annual Meeting of Stockholders on June 30, 2026. As of the May 5, 2026 record date, 123,432,072 shares of voting common stock were outstanding and entitled to vote.
Stockholders elected James B. Tananbaum, Lynn Tetrault and Zhengbin (Bing) Yao as Class II directors to serve until the 2029 Annual Meeting of Stockholders. Stockholders also ratified the Audit Committee’s appointment of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026, with 105,924,017 votes for, 283,113 against and 242,002 abstentions.
Alumis Inc. furnished an updated corporate presentation for investors, analysts, and other stakeholders. The presentation, dated June 2026, is available on the company’s website and attached as Exhibit 99.1.
The material is furnished, not filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.
Alumis Inc. Chief Medical Officer Jorn Drappa exercised stock options to acquire 26,852 shares of common stock. The Form 4 shows two option exercises on May 22, 2026, covering 15,535 shares at an exercise price of $5.06 per share and 11,317 shares at $8.84 per share. All transactions are coded as exercises of derivative securities, with no open-market purchases or sales reported in this filing.
Alumis Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 30, 2026. Stockholders will elect three Class II directors to serve until the 2029 annual meeting and vote on ratifying PricewaterhouseCoopers LLP as independent auditor for fiscal 2026.
The meeting is online only via live audio webcast, with a record date of May 5, 2026. Alumis describes its classified board structure, independence determinations under Nasdaq rules, committee composition, and governance policies, including a lead independent director role and an insider trading policy that prohibits hedging and pledging of company stock.
Alumis Inc. reports Q1 2026 results showing it remains a clinical-stage company investing heavily in R&D while strengthening its balance sheet. Total revenue was $1.7 million, mainly from collaboration revenue, while net loss narrowed slightly to $93.1 million, or $0.74 per share, versus a $99.0 million loss a year earlier.
R&D expenses were $81.5 million and G&A expenses were $18.6 million, reflecting ongoing development programs and integration of the ACELYRIN merger. Alumis closed a January 2026 public equity offering, receiving $324.4 million in net proceeds, and ended March 31, 2026 with $569.5 million in cash, cash equivalents and marketable securities and total assets of $671.6 million.
The company maintains an accumulated deficit of $994.9 million and continues to expect substantial losses as it develops autoimmune therapies, but believes its current cash resources will fund operating and capital needs for at least 12 months from the financial statement issuance date. An at-the-market facility permits up to $300.0 million in additional stock sales, with no shares sold as of March 31, 2026.
Alumis Inc. reported first quarter 2026 results and highlighted strong Phase 3 data for its oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis. For the quarter ended March 31, 2026, total revenue was $1,741 (in thousands) compared with $17,389 (in thousands) a year earlier, with a net loss of $93,053 (in thousands) versus $98,963 (in thousands).
The Phase 3 psoriasis study showed robust skin clearance, with PASI 90 responses of 68.0% and 62.1% and PASI 100 responses of 41.0% and 39.5% at Week 24, along with improvements in quality of life and symptoms. Alumis plans to submit a New Drug Application for envudeucitinib in plaque psoriasis in the fourth quarter of 2026 and anticipates potentially pivotal Phase 2b topline data in systemic lupus erythematosus in the third quarter of 2026. Cash, cash equivalents and marketable securities contributed to total assets of $671,588 (in thousands) as of March 31, 2026.
ALUMIS Inc. Schedule 13G: Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report beneficial ownership of 7,362,035 shares of Common Stock, representing 5.98% of the class as of April 7, 2026.
The filing cites 123,139,425 shares outstanding as of March 12, 2026 (per the issuer's 10-K). Ownership is reported as shared voting and dispositive power of 7,362,035 shares by the reporting persons.